Involvement of the serotonergic system in the control of impulsivity in Tourette disorder : ARITEP
- Conditions
- Tourette disorderMedDRA version: 20.0Level: LLTClassification code: 10018271Term: Gilles de la Tourette's disorder Class: 10010331Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- CTIS2023-506370-13-00
- Lead Sponsor
- Hospices Civils De Lyon
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 20
Male or Female, Diagnosed with a Tourette Disorder following the DSM-5, Age between 18-65 years, Member of a social security scheme in France, Freely-given informed consent to participate to this study (written form), With a current treatment by aripiprazole already scheduled, With Tics compatible with TEP/fMRI exams, Having (for women only) effective contraception throughout participation in the study.
Male or Female, A serious not controlled psychiatric comorbidity, A serious, evolving or debilitating pathology with a potential influence on the study, Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin), Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia), Women breastfeeding, Protected or restricted person (administratively or in judicial terms), Participants to another study with radiations or radiotracers since less of one year, participants to a concomitant study, Do not speak french
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method